JP2023512519A - コロナウイルス感染症を予防および処置するための組成物および方法-sars-cov-2ワクチン - Google Patents
コロナウイルス感染症を予防および処置するための組成物および方法-sars-cov-2ワクチン Download PDFInfo
- Publication number
- JP2023512519A JP2023512519A JP2022546341A JP2022546341A JP2023512519A JP 2023512519 A JP2023512519 A JP 2023512519A JP 2022546341 A JP2022546341 A JP 2022546341A JP 2022546341 A JP2022546341 A JP 2022546341A JP 2023512519 A JP2023512519 A JP 2023512519A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sars
- protein
- cov
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/102—Coronaviridae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/102—Coronaviridae (F)
- C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (43)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969008P | 2020-01-31 | 2020-01-31 | |
| US62/969,008 | 2020-01-31 | ||
| US202062994630P | 2020-03-25 | 2020-03-25 | |
| US62/994,630 | 2020-03-25 | ||
| US202063014467P | 2020-04-23 | 2020-04-23 | |
| US63/014,467 | 2020-04-23 | ||
| US202063025782P | 2020-05-15 | 2020-05-15 | |
| US63/025,782 | 2020-05-15 | ||
| US202062705187P | 2020-06-15 | 2020-06-15 | |
| US62/705,187 | 2020-06-15 | ||
| US202062705308P | 2020-06-21 | 2020-06-21 | |
| US62/705,308 | 2020-06-21 | ||
| US202063043090P | 2020-06-23 | 2020-06-23 | |
| US63/043,090 | 2020-06-23 | ||
| US202062706366P | 2020-08-12 | 2020-08-12 | |
| US62/706,366 | 2020-08-12 | ||
| US202063066147P | 2020-08-14 | 2020-08-14 | |
| US63/066,147 | 2020-08-14 | ||
| US202062706676P | 2020-09-02 | 2020-09-02 | |
| US62/706,676 | 2020-09-02 | ||
| US202062706937P | 2020-09-18 | 2020-09-18 | |
| US62/706,937 | 2020-09-18 | ||
| US202062706958P | 2020-09-21 | 2020-09-21 | |
| US62/706,958 | 2020-09-21 | ||
| US202063198089P | 2020-09-28 | 2020-09-28 | |
| US63/198,089 | 2020-09-28 | ||
| US202063198306P | 2020-10-09 | 2020-10-09 | |
| US63/198,306 | 2020-10-09 | ||
| US202063112900P | 2020-11-12 | 2020-11-12 | |
| US63/112,900 | 2020-11-12 | ||
| CA3101131 | 2020-11-28 | ||
| CA3101131A CA3101131A1 (en) | 2020-01-31 | 2020-11-28 | Compositions and methods for preventing and treating coronavirus infection - sarscov-2 vaccines |
| US202063121482P | 2020-12-04 | 2020-12-04 | |
| US63/121,482 | 2020-12-04 | ||
| US202163133969P | 2021-01-05 | 2021-01-05 | |
| US63/133,969 | 2021-01-05 | ||
| US202163135182P | 2021-01-08 | 2021-01-08 | |
| US63/135,182 | 2021-01-08 | ||
| US202163141913P | 2021-01-26 | 2021-01-26 | |
| US63/141,913 | 2021-01-26 | ||
| US202163142977P | 2021-01-28 | 2021-01-28 | |
| US63/142,977 | 2021-01-28 | ||
| PCT/US2021/015946 WO2021155323A1 (en) | 2020-01-31 | 2021-01-30 | Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512519A true JP2023512519A (ja) | 2023-03-27 |
| JP2023512519A5 JP2023512519A5 (cg-RX-API-DMAC7.html) | 2024-02-07 |
Family
ID=77079265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546341A Withdrawn JP2023512519A (ja) | 2020-01-31 | 2021-01-30 | コロナウイルス感染症を予防および処置するための組成物および方法-sars-cov-2ワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20230075527A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4097122A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023512519A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220134622A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116096732A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022014808A2 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202204380A (cg-RX-API-DMAC7.html) |
| UY (1) | UY39060A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021155323A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021191743A (ja) * | 2020-04-22 | 2021-12-16 | ビオエンテッヒ・アールエヌエイ・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | コロナウイルスワクチン |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210260181A1 (en) * | 2014-09-16 | 2021-08-26 | Altimmune, Inc | Coronavirus immunogenic compositions and uses thereof |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| AU2021214064A1 (en) | 2020-01-27 | 2022-08-18 | Novavax, Inc. | Coronavirus vaccine formulations |
| TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗 |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| MX2022009688A (es) | 2020-02-07 | 2022-12-15 | Rnaimmune Inc | Composición y métodos de vacunas de arnm contra la nueva infección por coronavirus. |
| EP4103228A1 (en) | 2020-02-13 | 2022-12-21 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| BR112022016054A2 (pt) * | 2020-02-14 | 2022-10-11 | Altimmune Inc | Composições imunogênicas para coronavírus e usos das mesmas |
| CA3167052A1 (en) | 2020-02-14 | 2021-08-19 | Mary Jo Hauser | Vaccines and uses thereof to induce an immune response to sars-cov2 |
| GB2594683A (en) * | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| JP2023511780A (ja) | 2020-02-25 | 2023-03-22 | イノビオ ファーマシューティカルズ,インコーポレイティド | コロナウイルスに対するワクチンおよび使用方法 |
| US11213482B1 (en) * | 2020-03-05 | 2022-01-04 | University of Pittsburgh—Of the Commonwealth System of Higher Educat | SARS-CoV-2 subunit vaccine and microneedle array delivery system |
| US20210341480A1 (en) * | 2020-04-29 | 2021-11-04 | Shi-long LU | Viral testing in saliva |
| US12226431B2 (en) | 2021-09-11 | 2025-02-18 | Porosome Therapeutics, Inc. | Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| US20230190917A1 (en) * | 2020-05-20 | 2023-06-22 | Alexandru Adrian Hennrich | Viral vaccine vector for immunization against a betacoronavirus |
| AU2021279079A1 (en) * | 2020-05-29 | 2022-12-15 | Board Of Regents, The University Of Texas System | Engineered coronavirus spike (s) protein and methods of use thereof |
| WO2021239880A1 (en) * | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| WO2021245611A1 (en) * | 2020-06-05 | 2021-12-09 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
| WO2021249011A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| US20230314432A1 (en) * | 2020-07-10 | 2023-10-05 | Covid Diagnostics Ltd. | Compositions, methods, and systems for detecting immune response |
| EP4182687A4 (en) * | 2020-07-20 | 2024-09-11 | Bio-Rad Laboratories, Inc. | IMMUNOASSAY FOR SARS-COV-2 NEUTRALISING ANTIBODIES AND MATERIALS THEREFOR |
| US20230272005A1 (en) * | 2020-07-31 | 2023-08-31 | Toagosei Co., Ltd. | Amino Acid Sequence Derived from Sars-Cov-2 and Use Thereof |
| US20220193225A1 (en) * | 2020-08-31 | 2022-06-23 | Bruce Lyday | Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins |
| WO2022041760A1 (en) | 2020-08-31 | 2022-03-03 | Sichuan Clover Biopharmaceuticals, Inc. | Methods and compositions for purification of trimeric fusion proteins |
| MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| WO2022159433A1 (en) * | 2021-01-20 | 2022-07-28 | Singh Biotechnology, Llc | Therapeutics directed against coronavirus |
| JP7598538B2 (ja) * | 2021-01-29 | 2024-12-12 | 東亞合成株式会社 | SARS-CoV-2由来のアミノ酸配列およびその利用 |
| EP4313143A4 (en) * | 2021-03-22 | 2025-06-18 | Novavax, Inc. | Coronavirus vaccine formulations |
| MX2023011227A (es) | 2021-03-22 | 2023-12-06 | Recode Therapeutics Inc | Composiciones y metodos para administracion dirigida a celulas. |
| MX2023011243A (es) | 2021-03-23 | 2023-12-14 | Recode Therapeutics Inc | Composiciones de polinucleotidos, formulaciones relacionadas y metodos de uso de los mismos. |
| US20240226273A1 (en) * | 2021-03-30 | 2024-07-11 | Arizona Board Of Regents On Behalf Of Arizona State University | Highly Attenuated Replication-Competent Recombinant Poxvirus As A Vaccine Platform And Methods Of Use |
| US20220324918A1 (en) * | 2021-03-30 | 2022-10-13 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF |
| US20220370598A1 (en) * | 2021-05-05 | 2022-11-24 | Inovio Pharmaceuticals, Inc. | Vaccines Against Coronavirus and Methods of Use |
| US20220370600A1 (en) * | 2021-05-21 | 2022-11-24 | Board Of Regents, The University Of Texas System | Multigenic mva-sars-cov-2 vaccine |
| TW202328166A (zh) | 2021-08-11 | 2023-07-16 | 美商達冕生物有限公司 | 針對新型冠狀病毒感染之mRNA疫苗之組成物及方法 |
| CN113832168B (zh) * | 2021-08-15 | 2023-08-04 | 北京科兴中维生物技术有限公司 | mRNA疫苗及其制备方法和应用 |
| WO2023020939A1 (en) * | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023023940A1 (zh) * | 2021-08-24 | 2023-03-02 | 复旦大学 | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 |
| WO2023026182A1 (en) | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023025287A1 (zh) * | 2021-08-26 | 2023-03-02 | 江苏瑞科生物技术股份有限公司 | 新型冠状病毒免疫原性物质、其制备方法和应用 |
| CN113913464B (zh) * | 2021-09-28 | 2022-11-22 | 武汉枢密脑科学技术有限公司 | 一种表达载体、重组腺相关病毒及其在制备2019新型冠状病毒疫苗中的应用 |
| WO2023092100A2 (en) * | 2021-11-19 | 2023-05-25 | Meissa Vaccines, Inc. | Methods of administering chimeric vaccines |
| CN116178527B (zh) * | 2021-11-26 | 2025-12-09 | 深圳先进技术研究院 | 抗sars-cov-2全人源单克隆抗体6g18及其制法与应用 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| KR20240125935A (ko) * | 2021-11-30 | 2024-08-20 | 노바백스, 인코포레이티드 | 코로나바이러스 백신 제형물 |
| US12616747B2 (en) | 2021-12-03 | 2026-05-05 | Board Of Regents, The University Of Texas System | Stabilized beta-coronavirus antigens |
| TWI843471B (zh) * | 2022-03-11 | 2024-05-21 | 財團法人國家衛生研究院 | 含抗原和dna之組成物及其用途 |
| CN114574502B (zh) * | 2022-04-11 | 2023-07-14 | 四川大学 | 一种以复制缺陷腺相关病毒为载体的新型冠状病毒疫苗 |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| TW202400635A (zh) * | 2022-04-20 | 2024-01-01 | 美商因諾維奧製藥公司 | 針對sars-cov-2變異體之免疫原性組合物及其使用方法 |
| WO2023212446A1 (en) * | 2022-04-29 | 2023-11-02 | Xequel Bio, Inc. | Compositions and methods for treating complications of viral infections and other respiratory disorders |
| WO2023240278A2 (en) * | 2022-06-10 | 2023-12-14 | The Trustees Of Columbia University In The City Of New York | Uses of glycolipids as a vaccine adjuvant and methods thereof |
| US11654121B1 (en) | 2022-06-22 | 2023-05-23 | Flagship Pioneering Innovations Vi, Llc | Combination therapies for the treatment of viral infections |
| WO2023250111A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Combination therapies for the treatment of viral infections |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| CA3261388A1 (en) * | 2022-07-07 | 2025-04-24 | Westvac Biopharma Co., Ltd. | Pharmaceutical composition to resist SARS-CoV-2 infection or a mutation thereof and a combination drug thereof |
| CN117448355A (zh) * | 2022-07-25 | 2024-01-26 | 艾棣维欣(苏州)生物制药有限公司 | 编码冠状病毒抗原的重组dna分子、dna疫苗及应用 |
| WO2024032468A1 (zh) * | 2022-08-08 | 2024-02-15 | 神州细胞工程有限公司 | 一种可诱导广谱中和活性重组五组分新冠病毒三聚体蛋白疫苗的制备及应用 |
| WO2024076805A2 (en) * | 2022-10-07 | 2024-04-11 | Zeptometrix Llc | Control for protein-based assay |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| WO2024097259A1 (en) * | 2022-11-01 | 2024-05-10 | RNAimmune, Inc. | Composition and methods for mrna vaccines against novel omicron coronavirus infections |
| CN116024269B (zh) * | 2022-11-18 | 2024-02-02 | 复百澳(苏州)生物医药科技有限公司 | 一种冠状病毒假病毒颗粒的制备方法 |
| CN116077635B (zh) * | 2022-11-23 | 2026-03-20 | 珠海市丽珠单抗生物技术有限公司 | 新型冠状病毒融合蛋白疫苗其应用 |
| CN116585465B (zh) * | 2023-04-19 | 2025-12-30 | 山东兴瑞生物科技有限公司 | 一种雾化吸入新冠疫苗及其制备方法 |
| WO2024229195A1 (en) * | 2023-05-03 | 2024-11-07 | Partner Therapeutics, Inc. | Viral infection modulation in vaccinated subjects treated with granulocyte-macrophage colony-stimulating factor (gm-csf) |
| EP4704881A2 (en) * | 2023-05-03 | 2026-03-11 | Partner Therapeutics, Inc. | Humoral modulation in vaccinated and virally infected subjects with granulocyte-macrophage colony-stimulating factor (gm-csf) |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5801030A (en) | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
| FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| KR100918187B1 (ko) | 1998-02-17 | 2009-09-22 | 쉐링 코포레이션 | 바이러스를 포함하는 조성물 및 바이러스 제제의 농축방법 |
| EP1133316B1 (en) | 1998-11-16 | 2009-01-21 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| WO2001036620A2 (en) | 1999-11-16 | 2001-05-25 | Genzyme Corporation | Vectors and transgenies with regulatory elements for gene delivery to the liver |
| EP2420247A1 (en) | 2000-03-07 | 2012-02-22 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
| WO2002092134A1 (en) | 2001-05-14 | 2002-11-21 | Cell Genesys, Inc. | Lentiviral vectors encoding clotting factors for gene therapy |
| CA2469491A1 (en) | 2001-12-12 | 2003-06-19 | Kerrie Setiawan | Composition for viral preservation |
| US20030232018A1 (en) | 2002-01-18 | 2003-12-18 | Berlex Biosciences | Stabilized formulations of adenovirus |
| US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| EP1649053A4 (en) | 2003-06-18 | 2006-10-18 | Chinese Nat Human Genome Ct Sh | CHARACTERIZATION OF THE EARLY LEVELS OF THE VIRUS OF HEAVY ACUTE RESPIRATORY SYNDROME (SARS) AND USES THEREOF |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| AU2004260884B2 (en) * | 2003-07-22 | 2009-11-19 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
| CN1977045A (zh) * | 2003-08-04 | 2007-06-06 | 马萨诸塞大学 | Sars核酸,蛋白质,疫苗以及它们的用途 |
| US7129042B2 (en) * | 2003-11-03 | 2006-10-31 | Diagnostic Hybrids, Inc. | Compositions and methods for detecting severe acute respiratory syndrome coronavirus |
| WO2005056585A2 (en) * | 2003-12-10 | 2005-06-23 | Agency For Science Technology And Research | Sars coronavirus s proteins and uses thereof |
| JP4814800B2 (ja) | 2004-01-23 | 2011-11-16 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | チンパンジーアデノウイルスワクチン担体 |
| US7741099B2 (en) | 2004-10-13 | 2010-06-22 | Beth Israel Deaconess Medical Center Inc. | Adenoviral vectors and uses thereof |
| BRPI0515819A (pt) | 2004-12-01 | 2008-08-05 | Genzyme Corp | métodos para o fornecimento direcionado de material genético ao fìgado |
| US8119140B2 (en) | 2005-08-23 | 2012-02-21 | Los Alamos Security, LLC | Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| WO2007110409A1 (en) | 2006-03-27 | 2007-10-04 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| EA019928B1 (ru) | 2008-11-03 | 2014-07-30 | Круселл Холланд Б.В. | Способ получения аденовирусных векторов |
| PL2358757T3 (pl) | 2008-11-18 | 2019-02-28 | Beth Israel Deaconess Medical Center | Szczepionki antywirusowe o ulepszonej immunogenności komórkowej |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| HUE039908T2 (hu) | 2009-02-02 | 2019-02-28 | Glaxosmithkline Biologicals Sa | Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk |
| PL2536829T3 (pl) | 2010-02-15 | 2016-09-30 | Sposób wytwarzania wektorów adenowirusowych Ad26 | |
| KR101879892B1 (ko) | 2010-12-14 | 2018-08-17 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 | 아데노바이러스 혈청형 26 및 혈청형 35 필로바일러스 백신 |
| GB201108879D0 (en) | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| JP5845376B2 (ja) * | 2012-03-22 | 2016-01-20 | クルセル ホランド ベー ヴェー | Rsvに対するワクチン |
| WO2018081318A1 (en) * | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| JP6721797B2 (ja) | 2017-02-09 | 2020-07-15 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 異種遺伝子発現のための強力で短いプロモーター |
| WO2018170347A1 (en) * | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| GB201708444D0 (en) | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Compositions and methods for inducing an immune response |
| MX421606B (es) | 2017-10-31 | 2025-03-14 | Janssen Vaccines & Prevention Bv | Vectores adenovirales y usos de estos |
| MX2020004488A (es) | 2017-10-31 | 2020-08-13 | Janssen Vaccines & Prevention Bv | Adenovirus y usos de estos. |
| SG11202003399TA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus and uses thereof |
| RU2709659C1 (ru) * | 2018-09-06 | 2019-12-19 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Иммунобиологическое средство и способ его использования для индукции специфического иммунитета к вирусу ближневосточного респираторного синдрома (варианты) |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| WO2021154763A1 (en) * | 2020-01-28 | 2021-08-05 | Modernatx, Inc. | Coronavirus rna vaccines |
| TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗 |
| KR20230009466A (ko) * | 2020-05-11 | 2023-01-17 | 얀센 파마슈티칼즈, 인코포레이티드 | SARS-CoV-2 백신 |
| US10906944B2 (en) | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
-
2021
- 2021-01-30 TW TW110103610A patent/TW202204380A/zh unknown
- 2021-01-30 US US17/759,803 patent/US20230075527A1/en not_active Abandoned
- 2021-01-30 CN CN202180025856.2A patent/CN116096732A/zh active Pending
- 2021-01-30 WO PCT/US2021/015946 patent/WO2021155323A1/en not_active Ceased
- 2021-01-30 JP JP2022546341A patent/JP2023512519A/ja not_active Withdrawn
- 2021-01-30 US US17/163,357 patent/US11498944B2/en active Active
- 2021-01-30 EP EP21747489.9A patent/EP4097122A4/en not_active Withdrawn
- 2021-01-30 BR BR112022014808A patent/BR112022014808A2/pt not_active IP Right Cessation
- 2021-01-30 KR KR1020227030114A patent/KR20220134622A/ko not_active Withdrawn
- 2021-02-01 UY UY0001039060A patent/UY39060A/es unknown
- 2021-07-28 US US17/387,105 patent/US11384122B2/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021191743A (ja) * | 2020-04-22 | 2021-12-16 | ビオエンテッヒ・アールエヌエイ・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | コロナウイルスワクチン |
| JP7514206B2 (ja) | 2020-04-22 | 2024-07-10 | ビオンテック・ソシエタス・エウロパエア | コロナウイルスワクチン |
| US12133899B2 (en) | 2020-04-22 | 2024-11-05 | BioNTech SE | Coronavirus vaccine |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021155323A1 (en) | 2021-08-05 |
| CN116096732A (zh) | 2023-05-09 |
| US11498944B2 (en) | 2022-11-15 |
| US11384122B2 (en) | 2022-07-12 |
| KR20220134622A (ko) | 2022-10-05 |
| EP4097122A1 (en) | 2022-12-07 |
| US20210246170A1 (en) | 2021-08-12 |
| UY39060A (es) | 2021-10-29 |
| US20230075527A1 (en) | 2023-03-09 |
| EP4097122A4 (en) | 2024-07-17 |
| BR112022014808A2 (pt) | 2022-09-20 |
| TW202204380A (zh) | 2022-02-01 |
| US20210388032A1 (en) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11498944B2 (en) | Compositions and methods for preventing and treating coronavirus infection—SARS-CoV-2 vaccines | |
| CA3101131A1 (en) | Compositions and methods for preventing and treating coronavirus infection - sarscov-2 vaccines | |
| Jeyanathan et al. | Immunological considerations for COVID-19 vaccine strategies | |
| Hassan et al. | A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2 | |
| Matsuda et al. | A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity | |
| Qin et al. | Identification of novel T-cell epitopes on infectious bronchitis virus N protein and development of a multi-epitope vaccine | |
| JP2023514249A (ja) | コロナウイルス免疫原性組成物およびその使用 | |
| US10004796B2 (en) | Adenoviral vector-based vaccine against enterovirus infection | |
| US20230310583A1 (en) | Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof | |
| Liu et al. | Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection | |
| Hassan et al. | A gorilla adenovirus-based vaccine against Zika virus induces durable immunity and confers protection in pregnancy | |
| US20230242940A1 (en) | Methods of making and using a vaccine against coronavirus | |
| KR20240137110A (ko) | 오미크론 코로나바이러스 백신 구조체 및 이를 제조하고 사용하는 방법 | |
| Ohtsuka et al. | Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2 | |
| Wang et al. | Development and identification of porcine monoclonal antibodies against PEDV from single B cells | |
| JP2025518717A (ja) | 弱毒化生SARS-CoV-2ワクチン | |
| JP2025504431A (ja) | レンチウイルスベースの経鼻ワクチンによるSARS-CoV-2免疫のブースト | |
| US20230227848A1 (en) | Coronavirus vaccine constructs and methods of making and using same | |
| Wang et al. | The pentameric complex is not required for vertical transmission of cytomegalovirus in seronegative pregnant rhesus macaques | |
| Moliva et al. | Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates | |
| Hassan et al. | A single intranasal dose of chimpanzee adenovirus-vectored vaccine confers sterilizing immunity against SARS-CoV-2 infection | |
| Bewley et al. | Immunological and pathological outcomes of SARS-CoV-2 challenge after formalin-inactivated vaccine immunisation of ferrets and rhesus macaques | |
| US20230065895A1 (en) | Poxviral-based vaccine against severe acute respiratory syndrome coronavirus 2 and methods using the same | |
| WO2023020939A1 (en) | Sars-cov-2 vaccines | |
| Malhi | Designing a Next-generation Epstein-Barr Virus Vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240405 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20240621 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240621 |